Gilead's HIV Results Pass Tolerability Test, But Not With A Straight "A"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
By and large, Gilead’s latest Phase II results for its fixed-dose, four-drug "Quad" regimen for HIV and stand-alone data on its novel GS-9350 booster satisfied clinicians and analysts when it came to the commercially crucial tolerability test.
You may also be interested in...
Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns
The four-drug combination pill for HIV has significant sales potential, and will be a mainstay for Gilead to protect its leadership in the market, but with two novel components there is still much work to be done.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product